(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
----------
AIM - WINNERS
----------
Blue Star Capital PLC, up 41% at 0.169 pence, 12-month range 0.11p-0.28p. Blue Star notes investee SatoshiPay says Pendulum, its smart contract network dedicated to connecting fiat payment networks to decentralised finance networks, has raised USD5 million by the private sale of PEN tokens. "The board of Blue Star believes the successful token presale and future launch of the Pendulum blockchain is a critical step towards SatoshiPay commercialising its core technology, thereby creating a number of advantages for SatoshiPay and its shareholders," the investor in esports, gaming and blockchain companies says.
----------
Warpaint London PLC, up 16% at 176.25p, 12-month range 63p-240p. The owner of the W7 and Technic make up brands says sales for 2021 now expected to be similar to 2019, when they totalled GBP49.3 million, as improving trends seen in first half of year continue. Adds that gross margins are currently being maintained ahead of those achieved in 2020 and 2019 despite increased costs in supply chain. Expects adjusted earnings before interest, tax, depreciation and amortisation and adjusted pretax profit to be both ahead of 2019 and current market expectations. Adjusted Ebitda in 2019 was GBP7.0 million and adjusted pretax profit was GBP5.2 million.
----------
Byotrol PLC, up 8.0% at 5.08p, 12-month range 4p-7.7p. The antimicrobial technologies and products developer says Nic Hellyer, part-time chief financial officer, intends to resign and company is in advanced talks to replace him with someone full-time. Rick Hayman, head of Byotrol's Professional division and managing director of Medimark Scientific Ltd, which Byotrol formally acquired in January 2020, has now left Byotrol, but remains a "supportive shareholder with a continued interest in the company's future".
----------
AIM - LOSERS
----------
Valirx PLC, down 17% at 43.5p, 12-month range 17.26p-63p. Signs letter of intent with TheoremRx Inc to sub-license ValiRx's legacy asset VAL201 for development in the treatment of cancer. ValiRx will retain the rights to develop the VAL201 peptide for non-oncology indications, including VAL301 for endometriosis. Says, subject to marketing authorisation, potential value of the deal would be in excess of USD61 million plus royalties for the first cancer indication alone. The letter of intent includes a period of exclusivity for TheoremRx to complete due diligence, and during this ValiRx is restricted from continuing to market the programme to other parties. Valirx stock price has more than doubled since 2021 began.
----------
Oncimmune Holdings PLC, down 14% at 167.13p, 12-month range 151p-261.63p. The immunodiagnostics company says revenue for financial year to May 31 jumps to GBP3.7 million from just GBP509,000 the year before and pretax loss narrows to GBP5.7 million from GBP9.8 million. Notes "quieter than expected summer months" in which fewer new ImmunoINSIGHTS contracts were signed than originally expected, but says there has been healthy resumption of activity.
----------
Feedback PLC, down 11% at 0.757p, 12-month range 0.6p-1.57p. The clinical communication company plans placing to raise minimum of GBP10 million at issue price of 0.7p per share. Also plans open offer to raise up to further GBP500,000. "Funds raised will be used primarily to support accelerated revenue growth through both private and public healthcare revenue opportunities within both the NHS and other healthcare systems in the UK and overseas," it says. Also on Tuesday, reports pretax loss of GBP2.1 million for financial year to May 31, widened from GBP1.4 million the year prior.
----------
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
